Healthcare >> Analyst Interviews >> October 21, 2002
Cardiology & Neuromodulation: Mark Landy – Leerink Swann & Co
MARK LANDY is a Vice President and Senior Research Analyst at
Leerink Swann & Company. Prior to joining the firm he was
associated with Investor AB, Merlin BioMed Group, and New Era
Capital. Mr. Landy earned a DDS from the University of the
Witwatersrand, South Africa, and a BBA from The Wharton School,
University of Pennsylvania. Mr. Landy is a member of the South
African Medical and Dental Council, the South African Society of
Surgeons, the British Medical Council and the British Dental
Association. JAN WALD joined A.G. Edwards in June 2000 and
focuses his research efforts in the medical technology industry.
Dr. Wald is an active publisher of industry and company-specific
research reports focused in the areas of cardiology and
neurology. He has previous work experience in the medical
technology industry, working at Guidant Corp. and Honeywell, Inc.
At Guidant, Dr. Wald managed clinical programs as well as the
development of the algorithms and software for two implantable
defibrillators. At Honeywell he managed image processing
algorithm and robotics programs. Prior to joining A.G. Edwards,
Dr. Wald was a Senior Vice President and Senior Analyst in
medical technology at George K. Baum & Co. He has a PhD from
Brandeis University and an MBA from University of St. Thomas. Dr.
Wald also holds a patent on atrial fibrillation detection. Profile
TWST: Could you define your coverage universe for us?
Mr. Landy: Currently we cover companies that participate in the
cardiovascular and neurovascular arena. In the cardiovascular